Microbiology Devices; Reclassification of Human Immunodeficiency Virus Viral Load Monitoring Tests
fda-device · Food and Drug Administration · Rule · Published 2022-11-04 · Effective 2022-12-05 · 87 FR 66545
Document
Document number
2022-23868
Federal Register citation
87 FR 66545
CFR reference
21 CFR 866
Type
Rule
Action
Final amendment; final order.
Category
fda-device
Sub-agency
Food and Drug Administration
Publication date
2022-11-04
Effective date
2022-12-05
HHS docket
Docket No. FDA-2020-N-2297
Abstract
The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order to reclassify human immunodeficiency virus (HIV) viral load monitoring tests, postamendments class III devices with the product code MZF, into class II (special controls), subject to premarket notification. Through this final order, FDA is also adding a new device classification regulation along with special controls that are necessary to provide a reasonable assurance of safety and effectiveness for this device type. The final order reclassifies this device type from class III (premarket approval) to class II (special controls) and will reduce the regulatory burdens associated with these devices because manufacturers will no longer be required to submit a premarket approval application (PMA) for this device type but can instead submit a less burdensome premarket notification (510(k)) and receive clearance before marketing their device.